Insulet Shares Slide After Q2 Beat, But Guidance Cut and Analyst Downgrades Weigh Heavily
Insulet Corporation's stock fell in pre-market trade after the company reported a strong second-quarter result but lowered its full-year U.S. growth forecast and trimmed revenue guidance. Management cited weaker-than-expected retention and utilization among type 2 diabetes patients in the first 90 days, and analysts responded with a string of downg…